Navigation Links
Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL
Date:12/7/2008

round 50%. Even for those who respond to treatment, recurrence of the disease is common.

A growing field of research on the cellular signaling associated with these lymphomas indicates that inhibiting Syk (spleen tyrosine kinase) in aberrant cells may control spread of the disease. Two additional research studies on the topic are also being presented at the ASH meeting. They are: Abstract 377, entitled "BCR, Signaling Diversity in Human Lymphoma B Cells Correlates with Follicular Lymphoma Patient Clinical Outcomes" and Abstract 802, entitled "BCL-6 Regulates Tonic BCR Signaling in Diffuse Large B-Cell Lymphomas." Further information on R788 in B-cell lymphoma is available at Rigel's website: http://www.rigel.com/rigel/lymphoma.

Conference Call and Webcast Information

To access the live call, please dial 800-561-2693 (domestic) or 617-614-3523 (international) 10 minutes prior to the start time and use the passcode 36883961. A replay of the call will be available, in webcast and podcast formats, at approximately 6:00 p.m. PST on December 7, 2008 through December 14, 2008. To access the replay, please dial 888-286-8010 (domestic) or 617-801-6888 (international) and use the passcode 47095093. The conference call will also be webcast live and can be accessed from Rigel's website at http://www.rigel.com. Please connect to Rigel's website several minutes prior to the start of the live webcast to ensure adequate time for any software downloads that may be necessary.

About Rigel (http://www.Rigel.com)

Rigel is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our pion
'/>"/>

SOURCE Rigel
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. OnKua, Launches Phase I Of "Phyzoom" A Web-Based Physician Marketing And Customer Relationship Management Product
2. MannKind Reports Positive Results from Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
3. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
4. SimQuest Awarded Phase 2 Contract from Office of the Secretary of Defense to Develop Pandemic Influenza Training Program
5. Neuromed Completes Enrollment for Phase 3 Chronic Low Back Pain Clinical Trial of NMED-1077
6. Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting
7. Hyperion Therapeutics Completes Phase 2 Data Analysis and Schedules End of Phase 2 Meeting With FDA for HPN-100 in the Chronic Treatment of Urea Cycle Disorders
8. Quigley Announces Completion of Phase IIb Clinical Study of QR-333 For Diabetic Peripheral Neuropathy on November 25, 2008; Collection and Evaluation of Study Data to Begin Immediately Thereafter
9. Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data
10. Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder
11. Ceregene Phase 2 Clinical Trial for Alzheimers Disease to be Funded by $5.4 Million Grant From National Institutes of Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... SonicSurg ... extremity surgical market, announced today that more than 600 successful patient procedures have ... hand. Plus, nearly 70 of these procedures have been on triggering thumbs. ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... SERVICE GROUP is internationally known as an industry leader specializing in surplus used ... world, selling more than 100,000 pieces of medical equipment every year. Erik Tivin, ...
(Date:9/2/2015)... VA (PRWEB) , ... September 02, 2015 , ... ... of document imaging, content, records and case management solutions and services to both ... PurePAGE®, its Image Re-sizing and Image Clean-up utility for IBM’s Datacap document capture ...
(Date:9/2/2015)... ... September 02, 2015 , ... Ovarian cancer continues to be the deadliest ... getting ovarian cancer in her lifetime is approximately 1 in 75. This year it ... and 14,000 will die. , There is no test to detect ovarian cancer. ...
(Date:9/2/2015)... ... 02, 2015 , ... On September 9, 2015, over 27,000 people from all ... single-company convention to date for the state of Utah. , “We are thrilled with ... states David Stirling, doTERRA CEO. “One of the most exciting elements of our convention ...
Breaking Medicine News(10 mins):Health News:Trigger Tome Surpasses 600 Successful Patient Procedures 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 2Health News:National Ovarian Cancer Coalition's DFW Chapter Features First Annual Teal Lights Display This Friday, September 4th, "National Wear Teal Day" 3Health News:doTERRA to Host the Largest Single-Company Convention in the State of Utah 2
... a randomized controlled study based in Los Angeles, California, encouraging ... with scripture reading and group prayer, led to a 78% ... miles. This increase was four times greater than in ... with no faith based interventions. The results are published ...
... among adult Americans when compared to peers in England ... than conventional risk factors such as obesity, according to ... University College London and the Institute for Fiscal Studies ... evidence that accumulating fat around the mid-section poses a ...
... their diabetes with a doctor in their own language may ... according to a new study by researchers at UCSF and ... that, among Latino diabetes patients with limited English skills, those ... to have poor control of their blood sugar than those ...
... DALLAS Oct. 7, 2010 Keeping blood pressure at ... the progression of the condition in patients with proteinuria, UT ... in The New England Journal of Medicine . ... AASK, trial of 1,094 patients, researchers found that keeping blood ...
... 19󈞀, 2010, Mayo Clinic,s Sports Medicine Center will ... summit will bring together top scientists, trainers, coaches, ... Canada and Europe to discuss concussion-related issues, including ... sporting world response. While the summit will focus ...
... ATLANTAOctober 6, 2010 The American Cancer Society, the ... the United States, has awarded 93 national research and ... the first of two grants cycles for 2011. The ... the grants are two American Cancer Society Research Professors: ...
Cached Medicine News:Health News:Study shows faith-based interventions can encourage exercise in older African-American women 2Health News:Study links large waist size to higher diabetes rates among Americans 2Health News:Study links large waist size to higher diabetes rates among Americans 3Health News:Patient-provider language barriers linked to worse diabetes control 2Health News:Keeping blood pressure in check may benefit some African-Americans with kidney disease 2Health News:Keeping blood pressure in check may benefit some African-Americans with kidney disease 3Health News:American Cancer Society awards new research and training grants 2Health News:American Cancer Society awards new research and training grants 3Health News:American Cancer Society awards new research and training grants 4Health News:American Cancer Society awards new research and training grants 5Health News:American Cancer Society awards new research and training grants 6
(Date:9/2/2015)... Nepstar Chain Drugstore Ltd. (NYSE: NPD ) ("Nepstar" ... China based on the number of directly operated stores, ... quarter ended June 30, 2015. Financial HighlightsFor ... increased by 12.9% to RMB775.1 million (US$125.0 million) compared ... , Same store sales increased by 16.7% compared ...
(Date:9/1/2015)... 2, 2015 The latest ... clinical trials review of H2, 2015 provides an ... objective to enhance decision making capabilities of active ... on Keratoconus market clinical trials review spread across ... / government organizations and supported with 43 tables ...
(Date:9/1/2015)... Mass. , Sept. 1, 2015  Shareholder rights ... whether certain officers and directors of ConforMIS, Inc. (NASDAQGS: ... ConforMIS is a medical technology company that uses its ... joint replacement implants that are individually sized and shaped ... this press release on the law firm,s Shareholder Rights ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 2China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 3China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 4China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 5China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 6China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 7China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 8China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 9China Nepstar Chain Drugstore Ltd. Reports Second Quarter 2015 Financial Results 10Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 2Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 3Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 4Keratoconus Market Clinical Trials Review H2 2015 Global Research Report 5Robbins Arroyo LLP Is Investigating the Officers and Directors of ConforMIS, Inc. (CFMS) on Behalf of Shareholders 2
... One device provides both low ... a single gas source , Reduce ... number of SKUs dedicated to nebulizers ... of double or wye set ups ...
... achieves optimum lung penetration for maximum therapeutic ... 1.04-1.10 µ at 6-8 LPM. Latex-free components. ... ,As the world leader in airway management ... of proven technology by offering top brands ...
... is improved CNBT technology, which relieves the practitioner ... 15 minutes. HOPE allows you the ability to ... administration couldn't be easier, with a length of ... can turn the HOPE nebulizer into an inexpensive ...
... Thera-Mist® Air Entrainment Nebulizers deliver particulate humidity ... for your chronic secretion patients. For your ... your existing supply of sterile water., ... at FiO2's of 20-50% with a total ...
Medicine Products: